Online inquiry

IVTScrip™ mRNA-Anti-CD3E, NI-0401(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12401MR)

This product GTTS-WQ12401MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD3E gene. The antibody can be applied in Crohn's disease (CD), Psoriasis research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000733.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916
UniProt ID P07766
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E, NI-0401(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12401MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10444MR IVTScrip™ mRNA-Anti-MSTN, LY-2495655(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LY-2495655
GTTS-WQ312MR IVTScrip™ mRNA-Anti-IGF1R, 19D12(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 19D12
GTTS-WQ6047MR IVTScrip™ mRNA-Anti-IL6, CNTO 136(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CNTO 136
GTTS-WQ15125MR IVTScrip™ mRNA-Anti-ERBB2, SYD985(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA SYD985
GTTS-WQ14781MR IVTScrip™ mRNA-Anti-CD40, SGN-40(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SGN-40
GTTS-WQ2763MR IVTScrip™ mRNA-Anti-TNFSF11, AMG162(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG162
GTTS-WQ12857MR IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA OPN-305
GTTS-WQ13163MR IVTScrip™ mRNA-Anti-TNFRSF4, PF-04518600(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PF-04518600
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW